F-15063

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H29NO2
Molecular Weight	363.4926
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)CC2=CC=CC(OCCNCC3=CC=CC(=C3)C4=CCCC4)=C2O1

InChI

InChIKey=RAIDOKRWKAIHOH-UHFFFAOYSA-N

InChI=1S/C24H29NO2/c1-24(2)16-21-11-6-12-22(23(21)27-24)26-14-13-25-17-18-7-5-10-20(15-18)19-8-3-4-9-19/h5-8,10-12,15,25H,3-4,9,13-14,16-17H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C24H29NO2
Molecular Weight	363.4926
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

PubMed

Title	Date	PubMed
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.	2009-11-05	19464324
F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.	2009-10-12	19695244
F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.	2009-04-01	19326477
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.	2008-09-11	18640111
Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.	2008-02-26	18190908
Induction by antipsychotics of "win-shift" in the drug discrimination paradigm.	2007-07	17431135
F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.	2007-06	17453175
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.	2007-05	17375087
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.	2007-05	17375086
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.	2007-05	17375085
Optimisation of anti-psychotic therapeutics: a balancing act?	2007-05	17375084
Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.	2007-02-22	17300168

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:37:40 GMT 2025` Edited by `admin` on `Mon Mar 31 23:37:40 GMT 2025`
Record UNII	115OSL8W3F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(2-(2,2-DIMETHYL-2,3-DIHYDROBENZOFURAN-7-YLOXY)ETHYL)(3-(CYCLOPENTEN-1-YL)BENZYL)AMINE

Preferred Name

English

F-15063

Common Name

English

BENZENEMETHANAMINE, 3-(1-CYCLOPENTEN-1-YL)-N-(2-((2,3-DIHYDRO-2,2-DIMETHYL-7-BENZOFURANYL)OXY)ETHYL)-

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID001336131